Hypera S.A. (OTCMKTS:HYPMY - Get Free Report) was the recipient of a large decrease in short interest in the month of April. As of April 15th, there was short interest totalling 100 shares, a decrease of 98.3% from the March 31st total of 5,800 shares. Based on an average daily volume of 8,500 shares, the short-interest ratio is presently 0.0 days. Approximately 0.0% of the shares of the company are sold short.
Hypera Stock Performance
Shares of HYPMY traded up $0.06 during mid-day trading on Friday, hitting $4.21. 5,031 shares of the company's stock were exchanged, compared to its average volume of 8,272. The firm has a market capitalization of $2.66 billion, a P/E ratio of 10.51 and a beta of 0.75. Hypera has a fifty-two week low of $2.64 and a fifty-two week high of $6.03. The business's 50 day moving average is $3.42 and its two-hundred day moving average is $3.46. The company has a current ratio of 1.81, a quick ratio of 1.41 and a debt-to-equity ratio of 0.68.
Hypera (OTCMKTS:HYPMY - Get Free Report) last announced its earnings results on Wednesday, April 23rd. The company reported ($0.04) earnings per share for the quarter. Hypera had a net margin of 20.04% and a return on equity of 13.18%. The company had revenue of $184.34 million during the quarter.
Hypera Company Profile
(
Get Free Report)
Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Hypera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hypera wasn't on the list.
While Hypera currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
